Stockreport

QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer

Qiagen N.V. Common Shares  (QGEN) 
Last qiagen n.v. common shares earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corporate.qiagen.com/investor-relations
PDF The therascreen® KRAS RGQ PCR Kit receives U.S. regulatory approval from FDA for expanded scope to include use in guiding treatment with the newly approved therapy LUMAK [Read more]